Urothelial carcinoma (bladder + upper tract) · line 2 · Erdafitinib monotherapy (THOR cohort 1) — 2L+ FGFR2/3-altered metastatic urothelial carcinoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-ERDAFITINIB-UROTHELIAL-2L |
| ID | IND-UROTHELIAL-2L-ERDAFITINIB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-29 | pending_clinical_signoff |
| Diseases | DIS-UROTHELIAL |
| Sources | SRC-EAU-BLADDER-2024 SRC-NCCN-BLADDER-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for FGFR2/3-altered mUC post PD-(L)1. NCCN Cat 1 (2025); FDA full approval Jan 2024 (post-THOR cohort 1; converted from 2019 accelerated). Pivotal trial source (THOR cohort 1, Loriot NEJM 2023) NOT yet authored in KB — cited via SRC-NCCN-BLADDER-2025 + SRC-EAU-BLADDER-2024; flag for source-ingest follow-up. UA access: named-patient / Janssen EAP only. Pairs with IND-UROTHELIAL-METASTATIC-1L-EV-PEMBRO in 1L → 2L sequencing.
Used By
Algorithms
ALGO-UROTHELIAL-METASTATIC-2L- ALGO-UROTHELIAL-METASTATIC-2L
Indication
IND-UROTHELIAL-2L-PLATINUM-CHEMO- IND-UROTHELIAL-2L-PLATINUM-CHEMO
Regimen
REG-GEM-CARBO-UROTHELIAL- Gemcitabine + carboplatin (urothelial carcinoma, cisplatin-ineligible)